AAO highlights top November ophthalmology news

News from the American Academy of Ophthalmology annual meeting led November’s top ophthalmology headlines, with four of the month’s most-read articles coming from presentations given at the conference.

The meeting and its preceding subspecialty days took place in mid-November.

Here are the top five most-read headlines on Healio.com/OSN last month:

1. LASIK called safest, most successful elective procedure in the world

The latest peer-reviewed meta-analysis of worldwide scientific literature for LASIK shows the satisfaction rate for the procedure is up to 98% and nearly 90% of patients achieve 20/20 vision, according to a speaker at Refractive Surgery Subspecialty Day preceding the American Academy of Ophthalmology meeting. Read more.

2. FDA approves Light Adjustable Lens from RxSight

This is the first medical device system that can make adjustments to the lens power after cataract surgery to correct refractive errors. Read more.

3. ETDRS, ultra-widefield imaging on par for identifying retinopathy severity

In a baseline data review, ETDRS and ultra-widefield imaging appear comparable for determining diabetic retinopathy severity within the ETDRS fields, according to results of the ongoing Diabetic Retinopathy Clinical Research Network Protocol AA trial. Read more.

4. Novartis’ VEGF inhibitor demonstrates clinically relevant anatomic, visual gains

Novartis’ first-in-kind molecule brolucizumab achieved clinically relevant anatomic and visual acuity gains in patients with age-related macular degeneration with every-12-week dosing. Read more.

5. Twin lampalizumab trials fail to impact area of geographic atrophy

Lampalizumab failed to impact geographic area compared with sham treatment in two identically designed phase 3 studies — Chroma and Spectri. Read more.